| Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias RJ Brentjens, I Rivière, JH Park, ML Davila, X Wang, J Stefanski, C Taylor, ... Blood, The Journal of the American Society of Hematology 118 (18), 4817-4828, 2011 | 1567 | 2011 |
| Cardiac toxicity 4 to 20 years after completing anthracycline therapy LJ Steinherz, PG Steinherz, CTC Tan, G Heller, ML Murphy Jama 266 (12), 1672-1677, 1991 | 1301 | 1991 |
| Genomic correlates of clinical outcome in advanced prostate cancer W Abida, J Cyrta, G Heller, D Prandi, J Armenia, I Coleman, M Cieslik, ... Proceedings of the National Academy of Sciences 116 (23), 11428-11436, 2019 | 1048 | 2019 |
| Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. PA Meyers, G Heller, J Healey, A Huvos, J Lane, R Marcove, ... Journal of Clinical Oncology 10 (1), 5-15, 1992 | 836 | 1992 |
| Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer DC Danila, G Heller, GA Gignac, R Gonzalez-Espinoza, A Anand, ... Clinical cancer research 13 (23), 7053-7058, 2007 | 806 | 2007 |
| Concordance probability and discriminatory power in proportional hazards regression M Gönen, G Heller Biometrika 92 (4), 965-970, 2005 | 729 | 2005 |
| Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data HI Scher, X Jia, JS de Bono, M Fleisher, KJ Pienta, D Raghavan, G Heller The lancet oncology 10 (3), 233-239, 2009 | 725 | 2009 |
| Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin C May, S Rivella, J Callegari, G Heller, KML Gaensler, L Luzzatto, ... Nature 406 (6791), 82-86, 2000 | 717 | 2000 |
| Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes E Basch, X Jia, G Heller, A Barz, L Sit, M Fruscione, M Appawu, A Iasonos, ... JNCI: Journal of the National Cancer Institute 101 (23), 1624-1632, 2009 | 656 | 2009 |
| Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer HI Scher, D Lu, NA Schreiber, J Louw, RP Graf, HA Vargas, A Johnson, ... JAMA oncology 2 (11), 1441-1449, 2016 | 646 | 2016 |
| Comparison of immune reconstitution after unrelated and related T-cell–depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions TN Small, EB Papadopoulos, F Boulad, P Black, H Castro-Malaspina, ... Blood, The Journal of the American Society of Hematology 93 (2), 467-480, 1999 | 577 | 1999 |
| Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes KC Hsu, CA Keever-Taylor, A Wilton, C Pinto, G Heller, K Arkun, ... Blood 105 (12), 4878-4884, 2005 | 576 | 2005 |
| 17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/neu and Inhibits the Growth of Prostate Cancer Xenografts DB Solit, FF Zheng, M Drobnjak, PN Münster, B Higgins, D Verbel, ... Clinical cancer research 8 (5), 986-993, 2002 | 559 | 2002 |
| Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous … E Berman, G Heller, J Santorsa, S McKenzie, T Gee, S Kempin, S Gulati, ... | 534 | 1991 |
| Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions AM Boruchov, G Heller, MC Veri, E Bonvini, JV Ravetch, JW Young The Journal of clinical investigation 115 (10), 2914-2923, 2005 | 513 | 2005 |
| Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation E Doubrovina, B Oflaz-Sozmen, SE Prockop, NA Kernan, S Abramson, ... Blood, The Journal of the American Society of Hematology 119 (11), 2644-2656, 2012 | 460 | 2012 |
| Osteogenic sarcoma with clinically detectable metastasis at initial presentation. PA Meyers, G Heller, JH Healey, A Huvos, A Applewhite, M Sun, ... Journal of Clinical Oncology 11 (3), 449-453, 1993 | 458 | 1993 |
| Chemotherapy without irradiation--a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central … C Balmaceda, G Heller, M Rosenblum, B Diez, JG Villablanca, S Kellie, ... Journal of Clinical Oncology 14 (11), 2908-2915, 1996 | 423 | 1996 |
| Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer DR Shaffer, MA Leversha, DC Danila, O Lin, R Gonzalez-Espinoza, B Gu, ... Clinical cancer research 13 (7), 2023-2029, 2007 | 416 | 2007 |
| Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer HI Scher, G Heller, A Molina, G Attard, DC Danila, X Jia, W Peng, ... Journal of clinical oncology 33 (12), 1348, 2015 | 404 | 2015 |
